ClinicalTrials.gg
CompletedNCT06447415Updated Sep 29, 2025

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

A Phase 1 interventional study of HRS-7450 and 0.9% sodium chloride injection in Acute Ischemic Stroke, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Enrollment
471st of 563
64 · median 266
Started
2024
with 101 others
Phase 1
28 of 750
10 open now
Registered
466th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 471st largest by enrollment of the 563 interventional ones that give a count, is one of 102 that started in 2024, is one of 28 in phase 1, and was the 466th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand and voluntarily participate in this study, and sign an form (the informed consent form can be voluntarily signed by the individual or legal representative);
  2. 18 ≤ Age ≤ 80 years old;
  3. The onset time is within 4.5 to 24 hours, and medication can be completed within 24 hours of onset (onset time is defined as the patient's last normal time);
  4. Clinically diagnosed as acute ischemic stroke (diagnosis follows the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023);
  5. mRS score ≤ 2 before the first episode;
  6. When screening, the National Institutes of Health Stroke Scale (NIHSS) scores from 3 to 25 (including both ends);
  7. Female and male participants with fertility must agree to use efficient measures from the signing of the informed consent form until one month after the last administration of the drug, without a birth plan, and without donating sperm/eggs. (See "Contraceptive methods" in the attachment for details).

Exclusion criteria

Exclusion Criteria:

  1. Treatment with ateplase, teneplase, or other thrombolytic drugs;
  2. Proposed endovascular treatment;
  3. Intracranial hemorrhagic diseases;
  4. Aortic arch dissection;
  5. NIHSS awareness score 1a>2 points;
  6. Epileptic seizures or neurological dysfunction after seizures, or combined with other neurological/psychiatric disorders leading to uncooperative or non cooperative physical examinations;
  7. Non enhanced CT shows a low-density shadow greater than one-third of the blood supply area of the middle cerebral artery or an ASPECT score of less than 6 points in the anterior circulation;
  8. Previous history of intracranial hemorrhage;
  9. Intracranial tumors, arteriovenous malformations, and giant aneurysms;
  10. Acute occlusion of the internal carotid artery due to carotid artery dissection;
  11. Multiple infarcts in areas supplied by multiple large blood vessels;
  12. Have a history of ischemic stroke, severe traumatic brain injury, or intracranial or spinal surgery in the past month;
  13. Gastrointestinal or urinary system bleeding within the past 2 weeks;
  14. Major surgical procedures or severe injuries within the past 2 weeks;
  15. Arterial puncture that is difficult to compress and stop bleeding within the past week;
  16. Active visceral bleeding;
  17. After actively reducing blood pressure, systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 100mmHg;
  18. Screening period examination: Blood glucose\<2.8 or>22.2mmol/L, \<100 * 109/L, other findings suggestive of a high risk of bleeding;
  19. Within the past 3 months, acute ST segment elevation myocardial infarction (MI) and/or acute decompensated heart failure occurred, and/or >520 milliseconds, and/or due to acute coronary syndrome MI、 Hospitalization or involuntary coronary intervention for cardiac arrest; Or Grade III/IV heart failure; Or known to have ventricular tachycardia;
  20. History of severe liver disease, or (AST) and/or alanine aminotransferase (ALT) and/or glutamyltransferase (GGT) ≥ 3 x and/or total (TBIL) ≥ 2 x ULN.
  21. Severe kidney disease with clinical significance, or \<45mL/min/1.73 m2;
  22. Subjects with known potential bleeding constitution or coagulation dysfunction;
  23. Subjects with a known history of glucose-6-phosphate dehydrogenase deficiency or a family history;
  24. Known to be allergic to any component of HRS-7450 or its formulations or placebo;
  25. Received therapeutic or prophylactic doses of heparin treatment within 24 hours;
  26. Oral coumarin anticoagulants with an international standardized ratio >2.7;
  27. Use thrombin inhibitors, Xa factor inhibitors, or other anticoagulant drugs under study within48 hours;
  28. Use platelet IIb/IIIa receptor inhibitors within 48 hours;
  29. Pregnant women, or women of childbearing age who test positive for pregnancy, or those who are breastfeeding;
  30. Participate in clinical studies of other drugs or devices within the first three months of the screening period (sign an form and receive treatment with the trial drug/device);
  31. The terminal state of the disease, with an expected survival period of no more than 1 year;
  32. Other situations where the researcher deems it inappropriate to participate in this experiment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    HRS-7450

    Drug: HRS-7450

  • Placebo comparator
    0.9% sodium chloride injection

    Drug: 0.9% sodium chloride injection

Interventions

  • DrugHRS-7450

    HRS-7450 Injection

  • Drug0.9% sodium chloride injection

    0.9% sodium chloride injection

06

What researchers measure

Primary outcomes

  1. Symptomatic Intracranial Hemorrhage within 36 hours after the start of administration, The incidence of sICH

    Time frame: within 36 hours after the start of administration

Secondary outcomes

  1. 7 day mortality rate after administration

    Time frame: within 7days after the start of administration

  2. The incidence of sICH 7 days after administration

    Time frame: within 7days after the start of administration

  3. The incidence of ICH 7 days after administration

    Time frame: within 7days after the start of administration

  4. The incidence of systemic bleeding 7 days after administration

    Time frame: within 7days after the start of administration

  5. Effective reperfusion rate measured by 24-hour PWI or CTP

    Time frame: within 24 hours after the start of administration

  6. 24-hour MRA or CTA measurement of vascular reperfusion rate

    Time frame: within 24 hours after the start of administration

  7. Infarct core volume measured by CT or MRI at 5-7 days

    Time frame: within 5-7days after the start of administration

  8. 24-hour NIHSS score change

    Time frame: within 24 hours after the start of administration

  9. 24-hour good response rate (NIHSS score reduction greater than 8 points, or NIHSS score 0-1)

    Time frame: within 24 hours after the start of administration

  10. 7 day NIHSS score change

    Time frame: within 7days after the start of administration

  11. 7 day good response rate (NIHSS score reduction greater than 8 points, or NIHSS score 0-1)

    Time frame: within 7days after the start of administration

07

Study locations

1 site
  • The First Affiliated Hospital of Sun Yat sen University
    Guangzhou, Guangdong 510062, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Mar 2025, 7 months.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
Aug 6, 2024
Primary completionActual
Mar 18, 2025
CompletionActual
Jun 11, 2025
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06447415
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Aug 6, 2024
Primary completion
Mar 18, 2025
Completion
Jun 11, 2025
Last update
Sep 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion